Avella Specialty Pharmacy acquires Oncology Plus

PHOENIX, Ariz. — On the heels of its announcement that it had hired a new medical advisor, Avella Specialty Pharmacy on Monday announced that it had acquired Oncology Plus, a Tampa, Fla.-based  provider of patient-specific compounded therapies. Avella said that the acquisition would further its strategic vision to become the nation’s leading omni-site specialty pharmacy and add breadth to its compounding and oncology-focused capabilities and offerings. 

 

“Oncology Plus is dedicated to providing unsurpassed value to its customers while ensuring the highest levels of quality and safety,” Avella CEO Rebecca Shanahan said. “This aligns perfectly with Avella's own high standards for our business. As a result, the move to integrate the people and products of Oncology Plus within our own compounding capabilities will give us greater scale and unique capabilities to service all of the pharmacy outsourcing needs of our practice and hospital partners."

 

With the acquisition, Avella adds Oncology Plus’s 5,000-sq. ft. facility and its Logics+ proprietary ordering, dosing and pathway compliance software. The company said its oncology offerings now span across such sites of care as the physician’s office, retail pharmacies and hospitals, and it expands its offerings to include compounded and oral therapies. Avella also serves hospitals and health systems through its 340B drug discount program, and it has recently announced the acquisition of Texas-based Advanced Pharma. 

 

"We are very excited to become part of a specialty pharmacy with such a strong reputation for clinical excellence and high-quality compounding," said Zach Scholl, President of Oncology Plus. "Avella's national footprint, industry relationships and expertise in the oncology space, combined with the IV compounding capabilities of Oncology Plus, will uniquely position us as a leader in this marketplace."

 

Oncology Plus will be rebranded as part of Avella.